Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.625    -0.025 (-3.85%)
Bid:
0.60
Ask:
0.65
Spread: 0.05 (8.333%)
Market Cap: £2.83m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director Dealing

12 Dec 2017 10:17

RNS Number : 0902Z
Physiomics PLC
12 December 2017
 

12th December 2017

Physiomics plc

("Physiomics") or ("the Company")

 

Director Dealing

 

The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share:

 

Director

Number of shares sold

Sale price per share

Dr J Millen, CEO

240,000

8.3p

Dr C Chassagnole, COO

600,000

8.3p

 

Following the sales of shares, the total holdings of each Director of the Company will be as follows:

 

Dr Paul Harper 525,707

Dr Jim Millen 444,641

Dr Christophe Chassagnole 417,008

 

The total number of shares in issue remains 58,785,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Millen

2

Reason for the notification

a)

Position/status

Director, CEO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

240,000

d)

Aggregated information

- Aggregated volume

- Price

 

240,000

At 8.3p per share

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christophe Chassagnole

2

Reason for the notification

a)

Position/status

Director, COO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

600,000

d)

Aggregated information

- Aggregated volume

- Price

 

600,000

At 8.3p

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

 

 

 

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford

+44 (0) 161 832 2174

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHTTBMTMBBBBIR
Date   Source Headline
28th May 20267:00 amRNS-RHantavirus Translational Modelling Capability
27th May 20267:00 amRNSPhysiomics Awarded Multiple Contract Awards
26th May 20263:48 pmRNSHolding(s) in Company
21st May 20265:21 pmRNSHolding(s) in Company
15th May 20267:00 amRNSUpdate regarding CEO - Peter Sargent
12th May 20267:00 amRNSAppointment of Stewart Williams as Consultant
8th May 20267:00 amRNSStrategy Update
29th Apr 20266:15 pmRNSReplacement Result of Meeting and Board Changes
29th Apr 202611:00 amRNSResults of General Meeting and Board Changes
24th Apr 202610:30 amRNSReminder to Vote Against Resolutions
22nd Apr 20267:00 amRNSLaunch of Website for Requisitioned Meeting
17th Apr 20267:00 amRNSISS Voting Recommendation
14th Apr 20267:00 amRNSPhysiomics Awarded New Contract by Numab
8th Apr 20267:00 amRNSRequestioned GM and Investor Presentation
20th Mar 20269:45 amRNSHolding(s) in Company
20th Mar 20267:00 amRNSCancellation of General Meeting
18th Mar 20262:55 pmRNSResult of WRAP Retail Offer
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
16th Mar 20267:00 amRNSGeneral Meeting Request
16th Mar 20267:00 amRNSGeneral Meeting Request
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
11th Mar 20268:00 amRNSHolding(s) in Company
10th Mar 20267:01 amRNSWRAP Retail Offer for up to £49,999.98
16th Feb 20268:37 amRNSInterim Results
13th Feb 20262:23 pmRNSHolding(s) in Company
12th Feb 20267:00 amRNS-RPhysiomics Awarded New Contract
2nd Feb 202611:40 amRNSHolding(s) in Company
28th Jan 20267:00 amRNSPhysiomics Awarded New Contract by Numab
23rd Dec 20257:00 amRNSOptions Award
23rd Dec 20257:00 amRNSOptions Award
15th Dec 20257:00 amRNSPhysiomics Awarded Follow On Contract by UK Client
11th Dec 20257:00 amRNSPhysiomics Awarded New Contract by Numab
10th Dec 20257:00 amRNS-RPhysiomics Awarded New Contract by GARDP
8th Dec 20254:31 pmRNSHolding(s) in Company
4th Dec 20257:00 amRNS-RPhysiomics Awarded Two New Contracts
3rd Dec 20257:00 amRNSBoard Changes
18th Nov 20253:43 pmRNSResult of AGM
17th Oct 20257:00 amRNSNotice of AGM
30th Sep 20257:00 amRNSChange of Registered Office
29th Sep 20257:00 amRNSAnnual Financial Report
22nd Sep 20257:00 amRNSNotice of Results and Investor Presentation
6th Aug 20257:00 amRNSFollow-on Contract with UK Biotech Client
16th Jul 20257:00 amRNSContract Award
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSPlatform Implementation and Partnership Expansion
1st Jul 20257:00 amRNSContract Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.